PL3082850T3 - Celowana szczepionka DNA MSLN w immunoterapii nowotworu - Google Patents

Celowana szczepionka DNA MSLN w immunoterapii nowotworu

Info

Publication number
PL3082850T3
PL3082850T3 PL14821508T PL14821508T PL3082850T3 PL 3082850 T3 PL3082850 T3 PL 3082850T3 PL 14821508 T PL14821508 T PL 14821508T PL 14821508 T PL14821508 T PL 14821508T PL 3082850 T3 PL3082850 T3 PL 3082850T3
Authority
PL
Poland
Prior art keywords
dna vaccine
cancer immunotherapy
targeting dna
msln targeting
msln
Prior art date
Application number
PL14821508T
Other languages
English (en)
Inventor
Marco Springer
Heinz Lubenau
Original Assignee
Vaximm Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vaximm Gmbh filed Critical Vaximm Gmbh
Publication of PL3082850T3 publication Critical patent/PL3082850T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001166—Adhesion molecules, e.g. NRCAM, EpCAM or cadherins
    • A61K39/001168—Mesothelin [MSLN]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C12N1/205—Bacterial isolates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/36—Adaptation or attenuation of cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/542—Mucosal route oral/gastrointestinal
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • C12R2001/42—Salmonella
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
PL14821508T 2013-12-18 2014-12-17 Celowana szczepionka DNA MSLN w immunoterapii nowotworu PL3082850T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP13005896 2013-12-18
PCT/EP2014/003403 WO2015090584A1 (en) 2013-12-18 2014-12-17 Novel msln targeting dna vaccine for cancer immunotherapy
EP14821508.0A EP3082850B1 (en) 2013-12-18 2014-12-17 Msln targeting dna vaccine for cancer immunotherapy

Publications (1)

Publication Number Publication Date
PL3082850T3 true PL3082850T3 (pl) 2020-01-31

Family

ID=49876343

Family Applications (1)

Application Number Title Priority Date Filing Date
PL14821508T PL3082850T3 (pl) 2013-12-18 2014-12-17 Celowana szczepionka DNA MSLN w immunoterapii nowotworu

Country Status (19)

Country Link
US (2) US20160317634A1 (pl)
EP (1) EP3082850B1 (pl)
JP (1) JP6662787B2 (pl)
KR (1) KR20160130979A (pl)
CN (1) CN106061500A (pl)
AU (1) AU2014365900B2 (pl)
BR (1) BR112016014405A2 (pl)
CA (1) CA2932388A1 (pl)
DK (1) DK3082850T3 (pl)
ES (1) ES2747772T3 (pl)
HU (1) HUE045567T2 (pl)
IL (1) IL246170B (pl)
LT (1) LT3082850T (pl)
MX (1) MX2016007939A (pl)
PL (1) PL3082850T3 (pl)
RU (1) RU2016129044A (pl)
SG (1) SG11201604911VA (pl)
SI (1) SI3082850T1 (pl)
WO (1) WO2015090584A1 (pl)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2565201B1 (en) 2005-10-17 2014-11-26 Sloan-Kettering Institute For Cancer Research WT1 HLA class II-binding peptides and compositions and methods comprising same
EP2010209B1 (en) 2006-04-10 2016-06-15 Sloan Kettering Institute For Cancer Research Immunogenic wt-1 peptides and methods of use thereof
EP3520810A3 (en) 2012-01-13 2019-11-06 Memorial Sloan-Kettering Cancer Center Immunogenic wt1 peptides and use thereof
US10815273B2 (en) 2013-01-15 2020-10-27 Memorial Sloan Kettering Cancer Center Immunogenic WT-1 peptides and methods of use thereof
LT2945647T (lt) 2013-01-15 2021-02-25 Memorial Sloan Kettering Cancer Center Imunogeniniai wt-1 peptidai ir jų panaudojimo būdai
DK2988762T3 (en) * 2013-04-25 2018-07-16 Vaximm Ag SALMONELLA-BASED VECTORS FOR CANCER IMMUNITY TARGET TARGETED WILMS 'TUMORGEN WT1
PL3082850T3 (pl) 2013-12-18 2020-01-31 Vaximm Gmbh Celowana szczepionka DNA MSLN w immunoterapii nowotworu
KR20250024816A (ko) * 2015-06-18 2025-02-19 백심 아게 병용 요법을 위한 vegfr-2 표적화 dna 백신
AU2017295004B2 (en) * 2016-07-13 2020-08-13 NEC Oncolmmunity AS Process for the production of a DNA vaccine for cancer immunotherapy
EP3534935A1 (en) * 2016-11-04 2019-09-11 Vaximm AG Wt1 targeting dna vaccine for combination therapy
KR20190117603A (ko) * 2017-02-17 2019-10-16 백심 아게 신규 vegfr-2 표적화 면역요법상 접근법
SG11201908528UA (en) * 2017-03-17 2019-10-30 Vaximm Ag Novel pd-l1 targeting dna vaccine for cancer immunotherapy
CN111479590A (zh) 2017-12-13 2020-07-31 艾诺奥医药品有限公司 靶向间皮素的癌症疫苗及其使用
US20210213121A1 (en) * 2018-09-05 2021-07-15 Vaximm Ag Neoantigen targeting dna vaccine for combination therapy
AU2021208400A1 (en) 2020-01-13 2022-08-11 Vaximm Ag Salmonella-based DNA vaccines in combination with an antibiotic
CN119751681A (zh) * 2024-12-30 2025-04-04 北京百替生物技术有限公司 抗间皮素的单链抗体、mRNA及其应用和核酸药物

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5726288A (en) 1989-11-13 1998-03-10 Massachusetts Institute Of Technology Localization and characterization of the Wilms' tumor gene
CN1859851A (zh) * 2002-07-12 2006-11-08 约翰斯霍普金斯大学 间皮素疫苗与模型系统
US9200036B2 (en) * 2002-07-12 2015-12-01 The Johns Hopkins University Mesothelin vaccines and model systems
US20050175625A1 (en) * 2002-07-12 2005-08-11 The Johns Hopkins University Mesothelin vaccines and model systems
US20060068469A1 (en) 2004-08-17 2006-03-30 Research Development Foundation Bacterial vector systems
US8658778B2 (en) 2005-03-09 2014-02-25 Board Of Regents, The University Of Texas System hTMC promoter and vectors for the tumor-selective and high-efficient expression of cancer therapeutic genes
US7935804B2 (en) * 2006-03-01 2011-05-03 Aduro Biotech Engineered Listeria and methods of use thereof
WO2012149364A1 (en) 2011-04-28 2012-11-01 Diamond Don J Tumor associated vaccines and compositions for disrupting tumor-derived immunosuppression for use in combination cancer immunotherapy
BR112014015706A2 (pt) * 2011-12-22 2020-10-27 Vaximm Ag método para o cultivo de uma estirpe mutante atenuada de salmonella typhi, estirpe mutante atenuada de salmonella typhi e salmonella typhi ty21a
WO2014043637A1 (en) 2012-09-17 2014-03-20 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Multifunctional oral vaccine based on chromosome recombineering
DK2988762T3 (en) 2013-04-25 2018-07-16 Vaximm Ag SALMONELLA-BASED VECTORS FOR CANCER IMMUNITY TARGET TARGETED WILMS 'TUMORGEN WT1
PL3082850T3 (pl) 2013-12-18 2020-01-31 Vaximm Gmbh Celowana szczepionka DNA MSLN w immunoterapii nowotworu

Also Published As

Publication number Publication date
HUE045567T2 (hu) 2020-01-28
JP2017502692A (ja) 2017-01-26
LT3082850T (lt) 2019-11-11
US10441645B2 (en) 2019-10-15
RU2016129044A (ru) 2018-01-23
AU2014365900B2 (en) 2020-04-09
US20180064794A1 (en) 2018-03-08
EP3082850A1 (en) 2016-10-26
EP3082850B1 (en) 2019-08-28
DK3082850T3 (da) 2019-10-07
CA2932388A1 (en) 2015-06-25
US20160317634A1 (en) 2016-11-03
SG11201604911VA (en) 2016-07-28
MX2016007939A (es) 2016-10-28
IL246170A0 (en) 2016-07-31
CN106061500A (zh) 2016-10-26
ES2747772T3 (es) 2020-03-11
JP6662787B2 (ja) 2020-03-11
IL246170B (en) 2019-06-30
BR112016014405A2 (pt) 2018-02-20
AU2014365900A1 (en) 2016-07-14
KR20160130979A (ko) 2016-11-15
SI3082850T1 (sl) 2020-01-31
WO2015090584A1 (en) 2015-06-25

Similar Documents

Publication Publication Date Title
IL246170A0 (en) A new msln-targeted DNA vaccine for cancer immunotherapy
IL235890A0 (en) vaccine
SG10201911616QA (en) Individualized vaccines for cancer
GB201315946D0 (en) Oncology vaccine
GB201223386D0 (en) Vaccine
SG11201500396TA (en) Tumor vaccination
IL233771A0 (en) Immunogens for use in the HIV vaccine
ZA201500656B (en) Marker vaccine
ZA201408335B (en) Multivalent breast cancer vaccine
IL241109A0 (en) Targeted vaccines for veterinary use
SG11201401632WA (en) Antigen presenting cancer vaccine
EP2925332A4 (en) PLACENTAL IMP THERAPY AGAINST CANCER
PT3536334T (pt) Vacinas contra o cancro dirigidas a células estaminais cancerígenas
SMT201900521T1 (it) Vaccini individualizzati per il cancro
GB201301125D0 (en) Methods for improving the efficency of gene targeting
GB201210226D0 (en) Vaccine
GB201202090D0 (en) Vaccine
GB201107549D0 (en) Cancer vaccine
GB201217321D0 (en) Vaccine
GB201206169D0 (en) Vaccine
GB201205599D0 (en) Vaccine